Cannabinoid formulation benefits opioid-refractory pain

Cannabinoid formulation benefits opioid-Refractory pain
A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of The Journal of Pain.

(HealthDay) -- A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of The Journal of Pain.

Russell K. Portenoy, M.D., of the Beth Israel Medical Center in , and associates conducted a randomized, double-blind, placebo-controlled, graded-dose study of 263 patients with advanced and opioid-refractory pain. Participants were randomly allocated to receive low-, medium-, or high-dose nabiximols or placebo. During five-weeks of treatment, average pain, worst pain, and sleep were measured daily; and mood were also assessed.

The researchers found that, compared with placebo, the 30 percent responder rate primary analysis was not significant for nabiximols (P = 0.59). In a secondary continuous responder analysis of average daily pain, a significantly higher proportion of patients reported analgesia in the nabiximols group than placebo (P = 0.035), specifically for low-dose and medium-dose nabiximols (P = 0.008 and 0.039, respectively). Results were similar for mean average pain, mean worst pain, and mean sleep disruption in the low-dose group (P = 0.006, 0.011, and 0.003, respectively). There were no significant group differences seen in other . Dose-related adverse events were seen, with only the high-dose group comparing unfavorably with placebo.

"Based on the results of this dose-ranging study, nabiximols in a manageable dose range may prove to offer benefits to a very ill population with refractory pain," the authors write. "Confirmatory studies are strongly warranted."

The study was funded by GW Pharmaceuticals, which produces nabiximols, and Otsuka.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Low-dose CT noninferior for diagnosing appendicitis

date Apr 26, 2012

(HealthDay) -- For young adults with suspected appendicitis, low-dose computed tomography (CT) is noninferior to standard-dose CT with respect to negative appendectomy rates, according to a study published ...

Recommended for you

A high-fat diet may alleviate mitochondrial disease

date Jun 30, 2015

Mice that have a genetic version of mitochondrial disease can easily be mistaken for much older animals by the time they are nine months old: they have thinning grey hair, osteoporosis, poor hearing, infertility, ...

Cheek muscles hold up better than leg muscles in space

date Jun 30, 2015

It is well known that muscles need resistance (gravity) to maintain optimal health, and when they do not have this resistance, they deteriorate. A new report published in the July 2015 issue of The FASEB Journal, however, sugges ...

Sialic acid: A key to unlocking brain disorders

date Jun 30, 2015

A new report published in the July 2015 issue of The FASEB Journal suggests that a common molecule found in higher animals, including humans, affects brain structure. This molecule may play a significant role in how brain ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.